Citation Impact
Citing Papers
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
2012 Standout
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2018 Standout
Cytokines in inflammatory bowel disease
2014 Standout
Fecal Calprotectin More Accurately Reflects Endoscopic Activity of Ulcerative Colitis than the Lichtiger Index, C-reactive Protein, Platelets, Hemoglobin, and Blood Leukocytes
2013
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial
2006 Standout
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
2013 Standout
Review article: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease
2011
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
2011
Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome
2015 StandoutNature
Microbial tryptophan catabolites in health and disease
2018 Standout
Ulcerative Colitis
2011 Standout
European evidence based consensus for endoscopy in inflammatory bowel disease
2013 Standout
Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease
2008
Clinical, biological, and endoscopic responses to adalimumab in antitumor necrosis factor-naive Crohn’s disease
2015
Adalimumab safety in global clinical trials of patients with Crohnʼs disease
2009
Sphingolipids and their metabolism in physiology and disease
2017 Standout
Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab
2010
Taurolidine 2% as an Antimicrobial Lock Solution for Prevention of Recurrent Catheter‐Related Bloodstream Infections
1998
Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab
2009
Functional Selectivity and Classical Concepts of Quantitative Pharmacology
2006 StandoutNobel
Guidelines for the management of inflammatory bowel disease in adults
2011
Anti–Tumor Necrosis Factor-α Antibodies Induce Regulatory Macrophages in an Fc Region-Dependent Manner
2010
Use of thiopurines in inflammatory bowel disease: Safety issues
2014
Inflammatory bowel disease: clinical aspects and established and evolving therapies
2007 Standout
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
2012
Crohn's disease
2012 Standout
Placental Transfer of Anti–Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel Disease
2012
The Science of Stroke: Mechanisms in Search of Treatments
2010 Standout
How Rapidly Should Remission Be Achieved?
2010
Functional Modulation of Crohn’s Disease Myofibroblasts by Anti-Tumor Necrosis Factor Antibodies
2007
Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease
2010
Psoriasis
2021 Standout
Inflammatory bowel disease: cause and immunobiology
2007 Standout
Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials
2013
Differential regulation of interleukin 17 and interferon production in inflammatory bowel disease
2009
Psoriasis: Which therapy for which patient
2018
Optimizing the safety of biologic therapy for IBD
2010
Inflammatory Bowel Disease
2009 Standout
Nitric Oxide and Peroxynitrite in Health and Disease
2007 Standout
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
2007
IL-6 as a keystone cytokine in health and disease
2015 Standout
Therapeutic targeting of α4-integrins in chronic inflammatory diseases: tipping the scales of risk towards benefit?
2005
A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease
2008
Biological Therapies for Inflammatory Bowel Diseases
2009
Glutamate neurotoxicity and diseases of the nervous system
1988 Standout
Inflammation and Colon Cancer
2010 Standout
Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin
2008
Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn's Disease: Results From the CHARM Study
2008
Ulcerative colitis
2012 Standout
Interleukin-17 and Type 17 Helper T Cells
2009 Standout
The development of molecular clamps as drugs
2006
Adalimumab for the treatment of fistulas in patients with Crohn’s disease
2009
Crohn's disease: beyond antagonists of tumour necrosis factor
2008
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
2021 Standout
Crohn's disease
2016 Standout
Probiotic Lactobacillus reuteri suppress proinflammatory cytokines via c-Jun
2008
Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: Experience from a consecutive cohort of inflammatory bowel disease patients
2011
Certolizumab Pegol for the Treatment of Crohn's Disease
2007
Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept
2005
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trial
2005
Ulcerative colitis
2016 Standout
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
2010
Evolving knowledge and therapy of inflammatory bowel disease
2006
Relationship of C-Reactive Protein With Clinical Response After Therapy With Ustekinumab in Crohn's Disease
2009
Accuracy of Magnetic Resonance Enterography in Assessing Response to Therapy and Mucosal Healing in Patients With Crohn's Disease
2013
Review article: altering the natural history of Crohn's disease – evidence for and against current therapies
2006
Safety and Efficacy of Adalimumab (D2E7) in Crohn's Disease Patients with an Attenuated Response to Infliximab
2005
Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases
2019 Standout
Immunomodulatory therapy for severe influenza
2011
Early symptomatic recurrence after intestinal resection in Crohn's disease is unpredictable
2007
Epidemiology and Natural History of Inflammatory Bowel Diseases
2011 Standout
New targets for mucosal healing and therapy in inflammatory bowel diseases
2013
Guidelines for the Prevention of Intravascular Catheter-related Infections
2011 Standout
The acute respiratory distress syndrome
2012 Standout
Opportunities for Treg cell therapy for the treatment of human disease
2023 StandoutNobel
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
2010 Standout
Peroxynitrite: biochemistry, pathophysiology and development of therapeutics
2007 Standout
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
2013 Standout
Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial
2012
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
2011 Standout
Detectable serum flagellin and lipopolysaccharide and upregulated anti-flagellin and lipopolysaccharide immunoglobulins in human short bowel syndrome
2007
The pros, cons, and many unknowns of probiotics
2019 Standout
Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: An open-label study
2007
A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease
2014
Inflammatory bone loss: pathogenesis and therapeutic intervention
2012 Standout
Therapeutic drug monitoring in patients with inflammatory bowel disease
2014
Suppression of colitis-driven colon cancer in mice by a novel small molecule inhibitor of sphingosine kinase
2010
An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease
2011
Macrophage Polarization
2016 Standout
Luminescent Chemodosimeters for Bioimaging
2012 Standout
Recognition between V- and dumbbell-shaped molecules
2013 StandoutNobel
Reversible Near-Infrared Fluorescent Probe Introducing Tellurium to Mimetic Glutathione Peroxidase for Monitoring the Redox Cycles between Peroxynitrite and Glutathione in Vivo
2013 Standout
Inflammatory Bowel Disease
2010 Standout
Emerging Treatment Options in Mild to Moderate Ulcerative Colitis.
2015
A Diet Low in Red and Processed Meat Does Not Reduce Rate of Crohn’s Disease Flares
2019 Standout
Fluorescent Chemosensors Based on Spiroring-Opening of Xanthenes and Related Derivatives
2011 Standout
Budesonide for induction of remission in Crohn's disease
2015
A Near-IR Reversible Fluorescent Probe Modulated by Selenium for Monitoring Peroxynitrite and Imaging in Living Cells
2011 Standout
Satellite Cells and the Muscle Stem Cell Niche
2013 Standout
Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab
2007
Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials
2008
Works of Paul Pollack being referenced
Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial
2006
Catheter‐Related Infections Associated With Home Parenteral Nutrition and Predictive Factors for the Need for Catheter Removal in Their Treatment
1994
A randomized, double-blind, placebo-controlled trial of the human anti-TNF-α monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn’s disease
2004
Achievement of Early Deep Remission Predicts Better Long-Term Outcomes for Adalimumab-Treated Patients with Crohnʼs Disease: Data from EXTEND
2010
Effect of Concomitant Steroid or Immunosuppressant Treatment on Adalimumab Response in Patients with Crohnʼs Disease
2008
Adalimumab Effectiveness in TNF-Antagonist-Naïve Patients and in Infliximab Nonresponders with Crohnʼs Disease
2008